Study Explains the Uptick of Prostate Cancer in World Trade Center First Responders

Article

Researchers conducted gene expression analyses on prostate cancer tumor samples from World Trade Center first responders and general population patients to see if there were any differences between the two.

Increased inflammation and immune response may partially explain the excess incidence of prostate cancer among first responders exposed to dust at the World Trade Center after the September 11, 2001 terrorist attacks, according to a study recently published in Molecular Cancer Research. The dust from the World Trade Center contained known carcinogens, such as benzene, asbestos, and dioxins.

Previous studies found an uptick of prostate cancer among World Trade Center first responders compared with the general population of New York state, but it has been unclear whether this epidemiological finding was actually due to an exposure or the result of surveillance bias.

Due to the possibility of chance associations in epidemiological studies, Michael Ittmann, MD, PhD, a professor of pathology at Baylor College of Medicine and co-leader of cancer biology at the Dan L Duncan Comprehensive Cancer Center in Houston, told Cancer Network that it’s “always important” to try to understand what the mechanism could be to determine whether an exposure is causative.

“As far as I know, [this study] is the only one that’s really looked at these causative mechanisms in this context,” he said.

He said this study provides a “mechanistic underpinning” for an increased incidence of prostate cancer among World Trade Center first responders and strengthens the findings of the epidemiologic studies.

To unearth a possible mechanism, the study researchers first conducted a gene expression analysis of immunologic and inflammatory genes in archived prostate cancer tumor samples from 15 patients who were World Trade Center first responders and 14 patients who were not. Compared with the control group, the World Trade Center first responder samples had a notable downregulation of genes involved in immune cell chemotaxis and proliferation, as well as a significant upregulation of genes involved in apoptosis and immune modulation. In addition, the pathways for DNA repair, G2–M checkpoint, and glycolysis were especially upregulated and the pathway for protein secretion was downregulated. Furthermore, three types of immune cells were significantly upregulated.

Study researchers further explored the acute effects of World Trade Center dust on the prostate by exposing rats with healthy prostates to the carcinogenic dust. Compared with a set of control rats who were not exposed, the prostate tissue of the exposed rats had an upregulation of antigen-presenting cells and B cells, suggesting the dust triggered an adaptive immune response. In addition, T-helper cell 17 (which is a subset of effector memory T cells) was upregulated and was one of the immune cells also upregulated in the archived human samples, indicating that the dust exposure lead to an inflammatory response.

The sole pathway found upregulated in the prostate tissue of exposed rats was the cholesterol synthesis pathway, which has been shown to be upregulated in prostate cancer tumors.

One possible application of these findings, Ittmann said, is earlier or more intensive screening of these first responders who may be at a higher risk of developing prostate cancer. In addition, he said the study findings may also be relevant to other kinds of occupational exposures that men may experience in other industries. In particular, the study researchers highlight populations of men exposed to environmental pollutants like that from motor vehicle emissions, industrial processes, power generation, and the household combustion of solid fuel.

Related Videos
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Financial constraints and a lack of education among some patients and providers must be addressed to improve the real-world use of certain prostate cancer therapies, says Neeraj Agarwal, MD.
Novel anti-PSMA monoclonal antibody rosopatamab is capable of carrying a bigger payload of radiation particles, which may potentially reduce doses for patients with prostate cancer, says Neeraj Agarwal, MD.
Related Content